Ludwig-Maximilians-Universität München
print

Language Selection

Breadcrumb Navigation


Content

ERC Advanced Grant

Restoring fluid homeostasis

München, 04/26/2016

Endocrinologist Martin Reincke’s ERC project sets out to elucidate the pathogenesis of the second most common cause of high blood pressure.

Professor ReinckeProfessor Dr. med. Martin Reincke is Director of Medical Clinic IV at the LMU Medical Center. As an endocrinologist, he specializes in clinical conditions linked to hormonal dysfunction.

In his ERC project, entitled “Pathophysiology of Primary Aldosteronism (PAPA)”, he plans to investigate the mechanisms responsible for elevated levels of the hormone aldosterone in the circulation – a condition which ranks as the second most prevalent cause of high blood pressure in the general population. Aldosterone is a mineralocorticoid hormone produced by the adrenal cortex, which plays a crucial role in the maintenance of water and sodium balance, and hence in the regulation of blood pressure. The underlying reasons for primary aldosteronism (overproduction of the hormone) remain unclear. Reincke’s principal aims are to analyze the molecular and humoral mechanisms that control the biosynthesis of the hormone, characterize the role of genetic factors in the regulation of the process and identify new therapeutic approaches for the treatment of the syndrome.

Martin Reincke was a member of the Medical Faculty at the Universität of Freiburg prior to his appointment to his present position at the LMU Medical Center. He has won several prizes for his work, including the Schoeller-Junkmann Prize for Research awarded by the German Society for Endocrinology and the Prize for Excellence in Teaching conferred by the Bavarian Ministry of Education and Cultural Affairs. Reincke is a member of the German National Academy of Sciences Leopoldina, and his research has been funded by agencies such as the Deutsche Forschungsgemeinschaft, the Federal Ministry for Research and Technology and the Deutsche Krebshilfe (German Cancer Aid).

For more on Martin Reincke’s research, see: